ChromaDex (NASDAQ:CDXC) Given New $8.10 Price Target at LADENBURG THALM/SH SH

ChromaDex (NASDAQ:CDXC) had its price target hoisted by stock analysts at LADENBURG THALM/SH SH from $6.80 to $8.10 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price target indicates a potential downside of 5.26% from the company’s previous close.

Several other research analysts also recently commented on CDXC. StockNews.com raised ChromaDex from a “buy” rating to a “strong-buy” rating in a research note on Monday, February 24th. Roth Mkm upped their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th.

ChromaDex Stock Up 52.7 %

Shares of CDXC stock traded up $2.95 during trading hours on Wednesday, reaching $8.55. The company’s stock had a trading volume of 18,667,777 shares, compared to its average volume of 822,043. ChromaDex has a fifty-two week low of $1.57 and a fifty-two week high of $9.18. The company has a market capitalization of $653.07 million, a price-to-earnings ratio of 855.86 and a beta of 2.21. The firm’s 50 day simple moving average is $5.62 and its 200-day simple moving average is $5.11.

Insider Transactions at ChromaDex

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the sale, the director now directly owns 244,179 shares in the company, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 9.64% of the company’s stock.

Hedge Funds Weigh In On ChromaDex

Several large investors have recently modified their holdings of CDXC. Barclays PLC increased its holdings in ChromaDex by 322.1% in the third quarter. Barclays PLC now owns 70,072 shares of the company’s stock valued at $256,000 after purchasing an additional 53,472 shares during the period. Sargent Investment Group LLC acquired a new stake in shares of ChromaDex in the fourth quarter valued at about $263,000. FMR LLC bought a new position in shares of ChromaDex during the third quarter worth about $55,000. JPMorgan Chase & Co. lifted its stake in shares of ChromaDex by 11.1% in the third quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock worth $1,211,000 after acquiring an additional 33,150 shares during the period. Finally, State Street Corp boosted its holdings in ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after acquiring an additional 62,692 shares during the last quarter. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.